ProKidney Corp.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Bruce Culleton
- Full Time Employees
- 231
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2000 Frontis Plaza Blvd. Winston-Salem NC United States of America 27103
- IPO Date
- Jun 30, 2021
- CIK
- 0001850270
- Website
- prokidney.com
- Similar Companies
- Business
- ProKidney Corp., founded in 2015 and headquartered in Winston-Salem, North Carolina, operates as a late clinical-stage biotechnology company specializing in innovative cellular therapies for chronic kidney disease (CKD). The company’s core product is rilparencel (also known as REACT®), a proprietary autologous cell therapy designed to preserve kidney function and potentially slow or reverse the progression of advanced CKD, particularly in patients with type 2 diabetes at high risk of kidney failure. ProKidney’s treatment platform utilizes Renal Advanced Therapies (RATs), leveraging enriched progenitor kidney cells aimed at regenerating damaged kidney tissue and improving function, along with diagnostic tools for early disease detection and patient support programs to enhance clinical outcomes. The company’s primary geographic focus is the United States, with ongoing Phase 2 and Phase 3 clinical trials evaluating the efficacy and safety of rilparencel, including the pivotal PROACT 1 study, which has enrolled over 50% of required patients and anticipates topline data in mid-2027. Recent major developments include the FDA’s acceptance of the estimated glomerular filtration rate (eGFR) slope as a surrogate endpoint for the accelerated approval pathway of rilparencel in advanced CKD patients with type 2 diabetes, marking a significant regulatory milestone. ProKidney also completed acquisitions in 2024, notably the $62 million purchases of inRegen and Twin City Bio, to expand its therapeutic pipeline targeting CKD. The company secured $825 million in funding through a SPAC merger, led by Social Capital Suvretta Holdings Corp. III, to support its late-stage clinical development and commercialization efforts. Presentations of late-breaking Phase 2 clinical trial results at major nephrology conferences in 2025 have further underscored ProKidney’s clinical momentum and visibility within the renal disease treatment community. ProKidney focuses on transforming CKD treatment from symptom management to regenerative repair, targeting healthcare providers, hospitals, and patient populations at risk of kidney failure. With control over its cell therapy production and extensive clinical evaluation, ProKidney aims to address the substantial unmet medical need in kidney disease treatment, positioning itself at the forefront of biotechnological innovation in nephrology. Its strategic expansions, regulatory achievements, and financial backing establish a strong foundation for anticipated commercial launch phases pending successful Phase 3 trial outcomes.
ProKidney Appoints Kenneth Locke as Chief Technical Officer
ProKidney Corp. (PROK) Reports Q1 Loss, Tops Revenue Estimates
ProKidney Reports First Quarter 2026 Financial Results and Business Highlights
Head-To-Head Contrast: ProKidney (NASDAQ:PROK) & Phio Pharmaceuticals (NASDAQ:PHIO)
ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer
ProKidney Corp. (NASDAQ:PROK) Given Consensus Recommendation of “Moderate Buy” by Brokerages
ProKidney (PROK) Projected to Post Earnings on Monday
ProKidney Stock: Differentiated CKD Approach Positions Rilparencel Favorably
ProKidney Corp. (PROK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
ProKidney to Present at the 44th Annual J.P. Morgan Healthcare Conference
ProKidney Corp. (NASDAQ:PROK) Receives Average Rating of “Hold” from Analysts
ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates
ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025
Head-To-Head Review: Tonix Pharmaceuticals (NASDAQ:TNXP) versus ProKidney (NASDAQ:PROK)
ProKidney to Participate in Two Upcoming Conferences: Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare Conference
ProKidney Announces Two Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2025
ProKidney: Slow-Burning 'Buy' Opportunity Based On 2027 Approval Of Kidney Disease Therapy
ProKidney Corp. (PROK) Presents At Citi's Biopharma Back To School Conference Transcript
ProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates
Meet the Biotech Stock That Rocketed 775% Higher